Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile

Zinger Key Points
  • Patients who switched to donidalorsen from prior prophylactics also showed a 62% further reduction in mean monthly HAE attack rates.
  • Ionis plans to file an FDA marketing application this year.

Friday, Ionis Pharmaceuticals Inc IONS announced results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE).

Donidalorsen had a favorable safety and tolerability profile across both studies, including when self-administered via an autoinjector.

Also Read: Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another.

Based on these data, Ionis is pursuing regulatory approval of donidalorsen as a potential treatment for HAE, a condition characterized by recurrent attacks of severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, stomach, face, and/or throat.

  • In the Phase 3 OASIS-HAE study, patients were treated with donidalorsen (80 mg) via subcutaneous injection every four weeks (Q4W) or every eight weeks (Q8W) or placebo over 24 weeks.
  • The study met its primary endpoint, demonstrating an 81% lower monthly HAE attack rate with donidalorsen Q4W compared to placebo over weeks one to 25 and a 55% reduction with Q8W.
    • In weeks five to 25, donidalorsen Q4W significantly reduced mean monthly HAE attack rates by 87% vs placebo.In the same time frame, treatment with donidalorsen Q4W reduced severe to moderate attacks per month by 89%.
    • Donidalorsen Q4W also reduced HAE attacks that require acute therapy by 92%.
  • Donidalorsen Q8W had a similar benefit as Q4W dosing over time on attack rate reduction and quality of life measures.
  • Donidalorsen was well-tolerated.

The OASIS-Plus open-label extension study results showed that Q4W patients and Q8W patients achieved 93% and 92% improvement from baseline in attack rates.

Patients who switched to donidalorsen from prior prophylactic treatment also showed a 62% further reduction in mean monthly HAE attack rates from baseline, and 84% of patients who switched reported a preference for donidalorsen.

Ionis plans to file an FDA marketing application this year.

Read Next: Genetic Medicines Focused-Ionis Pharmaceuticals’ Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows.

William Blair says, “Ultimately, we see donidalorsen’s profile as generally superior to current prophylactic options, with less frequent dosing and at-home autoinjector dosing potential being further differentiators.”

William Blair writes that the next 12-18 months could be a period of significant growth for Ionis and maintains its Outperform rating.

Price Action: IONS shares are up 3.15% at $37.70 at last check Friday.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechEquitiesNewsHealth CareReiterationAnalyst RatingsTrading IdeasGeneralBriefsExpert IdeasStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!